Biopharmaceutical benchmarks 2010
Over the past four years, several new types of experimental biologic treatment have received commercial registration, but the emergence of biosimilars represents the biggest shift in the biologic approval landscape.
Gespeichert in:
| Veröffentlicht in: | Nature biotechnology 2010-09, Vol.28 (9), p.917-924 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 924 |
|---|---|
| container_issue | 9 |
| container_start_page | 917 |
| container_title | Nature biotechnology |
| container_volume | 28 |
| creator | Walsh, Gary |
| description | Over the past four years, several new types of experimental biologic treatment have received commercial registration, but the emergence of biosimilars represents the biggest shift in the biologic approval landscape. |
| doi_str_mv | 10.1038/nbt0910-917 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_754030195</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2135394201</sourcerecordid><originalsourceid>FETCH-LOGICAL-c378t-1e77739f073c6bc95707377d3403bcc333cd6336707e9d030c39279afc35fd413</originalsourceid><addsrcrecordid>eNptkT1PwzAQhi0EoqUwsaOWhQECZ19ixyNUfEmVWGC2HMehKfkodjLw7zFKKQgx-WQ_eu78HiHHFC4pYHrVZB1ICpGkYoeMaRLziHLJd0MNqYiAJnxEDrxfAQCPOd8nIwYpkynjYzK7Kdv1UrtaG9t3pdHVNLONWdbavfkpAwqHZK_QlbdHm3NCXu5un-cP0eLp_nF-vYgMirSLqBVCoCxAoOGZkYkIlRA5xoCZMYhoco7Iw7WVOSAYlExIXRhMijymOCFng3ft2vfe-k7VpTe2qnRj294rkQQTUJkE8vQPuWp714ThAgQMOONpgM4HyLjWe2cLtXZl-NWHoqC-clOb3FTILdAnG2Wf1Tbfst9BBeBiAHx4al6t--n5v2824I3ueme3vl-7wk8Wyn5L</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>750206268</pqid></control><display><type>article</type><title>Biopharmaceutical benchmarks 2010</title><source>MEDLINE</source><source>Nature</source><source>Alma/SFX Local Collection</source><creator>Walsh, Gary</creator><creatorcontrib>Walsh, Gary</creatorcontrib><description>Over the past four years, several new types of experimental biologic treatment have received commercial registration, but the emergence of biosimilars represents the biggest shift in the biologic approval landscape.</description><identifier>ISSN: 1087-0156</identifier><identifier>EISSN: 1546-1696</identifier><identifier>DOI: 10.1038/nbt0910-917</identifier><identifier>PMID: 20829826</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>631/61/51 ; 692/308/153 ; Agriculture ; Antibodies, Bispecific - economics ; Antibodies, Bispecific - therapeutic use ; Benchmarking - standards ; Benchmarks ; Bioinformatics ; Biological Products - economics ; Biological treatment ; Biomedical and Life Sciences ; Biomedical Engineering/Biotechnology ; Biomedicine ; Biopharmaceutics - economics ; Biopharmaceutics - standards ; Biotechnology ; Cancer Vaccines - economics ; Drug Approval - statistics & numerical data ; Drug Industry - economics ; Drug Industry - standards ; Drugs, Generic - economics ; Europe ; Experiments ; FDA approval ; feature ; Life Sciences ; Marketing - economics ; Medical research ; Pharmaceutical industry ; Protein Engineering - economics ; United States</subject><ispartof>Nature biotechnology, 2010-09, Vol.28 (9), p.917-924</ispartof><rights>Springer Nature America, Inc. 2010</rights><rights>Copyright Nature Publishing Group Sep 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c378t-1e77739f073c6bc95707377d3403bcc333cd6336707e9d030c39279afc35fd413</citedby><cites>FETCH-LOGICAL-c378t-1e77739f073c6bc95707377d3403bcc333cd6336707e9d030c39279afc35fd413</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2727,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20829826$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Walsh, Gary</creatorcontrib><title>Biopharmaceutical benchmarks 2010</title><title>Nature biotechnology</title><addtitle>Nat Biotechnol</addtitle><addtitle>Nat Biotechnol</addtitle><description>Over the past four years, several new types of experimental biologic treatment have received commercial registration, but the emergence of biosimilars represents the biggest shift in the biologic approval landscape.</description><subject>631/61/51</subject><subject>692/308/153</subject><subject>Agriculture</subject><subject>Antibodies, Bispecific - economics</subject><subject>Antibodies, Bispecific - therapeutic use</subject><subject>Benchmarking - standards</subject><subject>Benchmarks</subject><subject>Bioinformatics</subject><subject>Biological Products - economics</subject><subject>Biological treatment</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedical Engineering/Biotechnology</subject><subject>Biomedicine</subject><subject>Biopharmaceutics - economics</subject><subject>Biopharmaceutics - standards</subject><subject>Biotechnology</subject><subject>Cancer Vaccines - economics</subject><subject>Drug Approval - statistics & numerical data</subject><subject>Drug Industry - economics</subject><subject>Drug Industry - standards</subject><subject>Drugs, Generic - economics</subject><subject>Europe</subject><subject>Experiments</subject><subject>FDA approval</subject><subject>feature</subject><subject>Life Sciences</subject><subject>Marketing - economics</subject><subject>Medical research</subject><subject>Pharmaceutical industry</subject><subject>Protein Engineering - economics</subject><subject>United States</subject><issn>1087-0156</issn><issn>1546-1696</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkT1PwzAQhi0EoqUwsaOWhQECZ19ixyNUfEmVWGC2HMehKfkodjLw7zFKKQgx-WQ_eu78HiHHFC4pYHrVZB1ICpGkYoeMaRLziHLJd0MNqYiAJnxEDrxfAQCPOd8nIwYpkynjYzK7Kdv1UrtaG9t3pdHVNLONWdbavfkpAwqHZK_QlbdHm3NCXu5un-cP0eLp_nF-vYgMirSLqBVCoCxAoOGZkYkIlRA5xoCZMYhoco7Iw7WVOSAYlExIXRhMijymOCFng3ft2vfe-k7VpTe2qnRj294rkQQTUJkE8vQPuWp714ThAgQMOONpgM4HyLjWe2cLtXZl-NWHoqC-clOb3FTILdAnG2Wf1Tbfst9BBeBiAHx4al6t--n5v2824I3ueme3vl-7wk8Wyn5L</recordid><startdate>20100901</startdate><enddate>20100901</enddate><creator>Walsh, Gary</creator><general>Nature Publishing Group US</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7QR</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>M7S</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20100901</creationdate><title>Biopharmaceutical benchmarks 2010</title><author>Walsh, Gary</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c378t-1e77739f073c6bc95707377d3403bcc333cd6336707e9d030c39279afc35fd413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>631/61/51</topic><topic>692/308/153</topic><topic>Agriculture</topic><topic>Antibodies, Bispecific - economics</topic><topic>Antibodies, Bispecific - therapeutic use</topic><topic>Benchmarking - standards</topic><topic>Benchmarks</topic><topic>Bioinformatics</topic><topic>Biological Products - economics</topic><topic>Biological treatment</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedical Engineering/Biotechnology</topic><topic>Biomedicine</topic><topic>Biopharmaceutics - economics</topic><topic>Biopharmaceutics - standards</topic><topic>Biotechnology</topic><topic>Cancer Vaccines - economics</topic><topic>Drug Approval - statistics & numerical data</topic><topic>Drug Industry - economics</topic><topic>Drug Industry - standards</topic><topic>Drugs, Generic - economics</topic><topic>Europe</topic><topic>Experiments</topic><topic>FDA approval</topic><topic>feature</topic><topic>Life Sciences</topic><topic>Marketing - economics</topic><topic>Medical research</topic><topic>Pharmaceutical industry</topic><topic>Protein Engineering - economics</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Walsh, Gary</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Nature biotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Walsh, Gary</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biopharmaceutical benchmarks 2010</atitle><jtitle>Nature biotechnology</jtitle><stitle>Nat Biotechnol</stitle><addtitle>Nat Biotechnol</addtitle><date>2010-09-01</date><risdate>2010</risdate><volume>28</volume><issue>9</issue><spage>917</spage><epage>924</epage><pages>917-924</pages><issn>1087-0156</issn><eissn>1546-1696</eissn><abstract>Over the past four years, several new types of experimental biologic treatment have received commercial registration, but the emergence of biosimilars represents the biggest shift in the biologic approval landscape.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>20829826</pmid><doi>10.1038/nbt0910-917</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1087-0156 |
| ispartof | Nature biotechnology, 2010-09, Vol.28 (9), p.917-924 |
| issn | 1087-0156 1546-1696 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_754030195 |
| source | MEDLINE; Nature; Alma/SFX Local Collection |
| subjects | 631/61/51 692/308/153 Agriculture Antibodies, Bispecific - economics Antibodies, Bispecific - therapeutic use Benchmarking - standards Benchmarks Bioinformatics Biological Products - economics Biological treatment Biomedical and Life Sciences Biomedical Engineering/Biotechnology Biomedicine Biopharmaceutics - economics Biopharmaceutics - standards Biotechnology Cancer Vaccines - economics Drug Approval - statistics & numerical data Drug Industry - economics Drug Industry - standards Drugs, Generic - economics Europe Experiments FDA approval feature Life Sciences Marketing - economics Medical research Pharmaceutical industry Protein Engineering - economics United States |
| title | Biopharmaceutical benchmarks 2010 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T12%3A03%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biopharmaceutical%20benchmarks%202010&rft.jtitle=Nature%20biotechnology&rft.au=Walsh,%20Gary&rft.date=2010-09-01&rft.volume=28&rft.issue=9&rft.spage=917&rft.epage=924&rft.pages=917-924&rft.issn=1087-0156&rft.eissn=1546-1696&rft_id=info:doi/10.1038/nbt0910-917&rft_dat=%3Cproquest_cross%3E2135394201%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=750206268&rft_id=info:pmid/20829826&rfr_iscdi=true |